This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Rite Aid Reports 0.7 Percent Same Store Sales Decrease For September

Rite Aid Corporation (NYSE: RAD) today announced sales results for September.

Monthly SalesFor the four weeks ended Sept. 29, 2012, same store sales decreased 0.7 percent over the prior-year period. September front-end same store sales increased 2.8 percent. Pharmacy same store sales, which included an approximate 911 basis points negative impact from new generic introductions, decreased 2.3 percent. Prescription count at comparable stores increased 4.4 percent over the prior-year period.

Total drugstore sales for the four-week period decreased 1.5 percent to $1.899 billion compared to $1.927 billion for the same period last year. Prescription sales accounted for 67.8 percent of drugstore sales, and third party prescription sales represented 96.5 percent of pharmacy sales.

Year-to-Date SalesSame store sales for the 30-week period ended Sept. 29, 2012 increased 0.9 percent over the prior-year period. Front-end same store sales increased 2.1 percent while pharmacy same store sales increased 0.4 percent. Prescription count at comparable stores increased 3.6 percent over the prior-year period.

Total drugstore sales for the 30 weeks ended Sept. 29, 2012 increased 0.2 percent with sales of $14.545 billion compared to $14.513 billion for the same period last year. Prescription sales represented 67.9 percent of total drugstore sales, and third party prescription sales represented 96.6 percent of pharmacy sales.

Rite Aid is one of the nation’s largest drugstore chains. On Sept. 29, 2012, the company operated 4,639 stores compared to 4,694 stores in the like period a year ago. Information about Rite Aid, including corporate background and press releases, is available through the company’s website at http://www.riteaid.com. Note that all sales data in this release is preliminary, unaudited and subject to revision.

Statements in this release that are not historical are forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are not guarantees of future performance and involve risks, assumptions and uncertainties that are described in Item 1A (Risk Factors) of our most recent Annual Report on Form 10-K and in other documents that we file or furnish with the Securities and Exchange Commission, which you are encouraged to read. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those indicated or anticipated by such forward-looking statements. Accordingly, you are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date they are made. Rite Aid expressly disclaims any current intention to update publicly any forward-looking statement after the distribution of this release, whether as a result of new information, future events, changes in assumptions or otherwise.



1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 18,080.14 +21.45 0.12%
S&P 500 2,117.69 +4.76 0.23%
NASDAQ 5,092.0850 +36.0220 0.71%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs